(Q35326859)

7 August 2017

1 reference

title

Efficacy of fluvoxamine in severe depression (English)

1 reference

7 August 2017

1 reference

J. Mendlewicz

1

1 reference

PubMed ID

1378372

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1378372

20 September 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

PubMed ID

1378372

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1378372

20 September 2022

publication date

1 January 1992

1 reference

7 August 2017

1 reference

7 August 2017

43 Suppl 2

1 reference

7 August 2017

32-7; discussion 37-9

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199200432-00006

7 August 2017

0 references

cites work

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

12 December 2020

A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression

1 reference

12 December 2020

Use of a standardized documentation system (BLIPS/BDP) in the conduct of a multicenter international trial comparing fluvoxamine, imipramine, and placebo.

1 reference

12 December 2020

Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group

1 reference

12 December 2020

A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients

1 reference

12 December 2020

A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression.

1 reference

12 December 2020

10.2165/00003495-199200432-00006

Identifiers

DOI

0 references

Dimensions Publication ID

0 references

1 reference

PubMed ID

1378372